In this section:

11 June 2018

New Biologic Approved in Scotland

The Scottish Medicines Consortium has today published its acceptance of guselkumab (Tremfya) as a treatment for severe psoriasis in Scotland.

Guselkumab (Tremfya) is recommended to treat severe psoriasis, where people have not had adequate results from conventional systemic treatments, or cannot take them. You can read the complete guidance by clicking here.

Tremfya blocks the activity of interleukin 23 (IL-23), a chemical ’messenger’ in the immune system that signals other cells to cause inflammation. In people with psoriasis the immune system is overactive and creates too much inflammation, which leads to the development of psoriasis symptoms. By blocking IL-23, Tremfya aims to prevent some of that inflammation from occurring, leading to an improvement in psoriasis for some people who take it. There is currently one other biologic medication available that blocks the activity of IL-23 available for people with severe psoriasis, called Stelara (ustekinumab).

The National Institute for Health and Care Excellence (NICE) is also in the process of appraising guselkumab (Tremfya) to treat severe psoriasis in England and Wales. NICE recently indicated that it would be approving the treatment, but the full guidance is expected later in June 2018.

For more information on Tremfya, please click here.

The Psoriasis Association is the UK's leading national charity and membership organisation for people affected by psoriasis – patients, families, carers and health professionals Read More >

Get in touch

The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF


Tel :
01604 251 620
Fax :
01604 251 621
Registered with Fundraising Regulator -

© The Psoriasis Association Charitable Incorporated Organisation Number: 1180666 Scotland: SC039886 Privacy PolicyCookies

Site by Spoken Image | glitterfish

We use cookies to help us provide you with a better service, but do not track anything that can be used to personally identify you.

If you prefer us not to set these cookies, please visit our Cookie Settings page or continue browsing our site to accept them.